|
Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies |
The Johns Hopkins University School of Medicine |
Flashes of Hope, The ChadTough Defeat DIPG Foundation |
|
Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor |
Ann & Robert H. Lurie Children’s Hospital of Chicago |
Tap Cancer Out, Emily’s Smiles Foundation |
|
Epigenetic Targeted Therapy and Resistance in Pediatric Rhabdoid Tumor |
Ann & Robert H. Lurie Children’s Hospital of Chicago |
Tap Cancer Out, Emily’s Smiles Foundation |
|
Therapeutic Targeting of Childhood Leukemia by Pharmacological Inhibition of Proteolytic Cleavage of MLL1 |
Northwestern University (Illinois) |
Northwestern Mutual Foundation |
|
Investigating the role of BAI1 in the Metastasis of Medulloblastoma |
University of Alabama at Birmingham |
Northwestern Mutual Foundation |
|
Effect of SLCO Polymorphisms on High-Dose Methotrexate Clearance in Pediatric Oncology Patients |
Vanderbilt University Medical Center |
Cure4Cam Childhood Cancer Foundation |
|
Targeting the Metabolic Drivers of Chemo Resistance in Acute Myeloid Leukemia |
Harvard University |
Tap Cancer Out |
|
Augmenting Chimeric Antigen Receptor T Cell Induced Epitope Spreading for Pediatric Solid Tumors |
Children’s Hospital of Philadelphia |
SebastianStrong Foundation |
|
MYC-driven Core Regulatory Circuits in Neuroblastoma |
Dana-Farber Cancer Institute |
Flashes of Hope |
|
Novel Antibodies to the C2-set Domain of CD33 for Acute Myeloid Leukemia Immunotherapy |
Fred Hutchinson Cancer Research Center |
Northwestern Mutual Foundation |
